New data suggest J&J vaccine works against delta variant and recipients don’t need booster shot

A single dose of the COVID-19 vaccine made by Johnson & Johnson is highly effective in preventing severe illness and death from the delta and beta variants of the coronavirus, data from a clinical trial in South Africa suggest.

The study is the first real-world test of the vaccine’s efficacy against delta, a highly contagious variant of the virus surging across the United States and much of the world. South Africa’s Ministry of Health reported these preliminary results at a news conference Friday. The data have not yet been peer-reviewed or published in a scientific journal.


In the trial, called Sisonke, the researchers evaluated one dose of the Johnson & Johnson vaccine in nearly 500,000 health care workers, who are at high risk of COVID-19. The vaccine has an efficacy of up to 95% against death from the delta variant, and up to 71% against hospitalization, the researchers reported. (The vaccine did slightly worse against the beta variant, which is thought to be more adept at sidestepping the immune response than delta.)

“We believe this vaccine is doing what it was designed to do, which was to stop people going to hospital and stop them ending in ICUs and dying,” said Dr. Linda-Gail Bekker, co-lead of the study and director of the Desmond Tutu HIV Centre at the University of Cape Town.


The results suggest that people who have received one dose of the Johnson & Johnson vaccine don’t need a booster shot, Bekker said.

When so-called breakthrough infections did occur in vaccinated volunteers, they produced mild symptoms in 96% of the cases and resulted in severe disease or death in less than 0.05%, the study found. The trial ran from February to May of this year.

Breaking News Alerts

As it happens

Be informed of breaking news as it happens and notified about other don't-miss content with our free news alerts.

The results should comfort the millions of people who have received the J&J vaccine, particularly because some previous studies had suggested the single shot may be vulnerable to delta. Laboratory studies of the vaccine’s performance against the variant have been mixed, and a trial comparing the one- and two-dose regimens has not yet released results.

Given the uncertainty, some Johnson & Johnson recipients have sought a second dose on their own. Health officials in San Francisco are offering residents immunized with J&J a supplemental dose of the Pfizer-BioNTech or Moderna vaccines.

South Africa approved the J&J vaccine in April. The country battled a surge of the beta variant of the virus earlier this year, but delta has become the dominant variant in recent weeks. More than 8 million South Africans have received the J&J vaccine or at least one dose of the Pfizer vaccine.

“This study was conducted as a real-world efficacy study in one of the most challenging epidemiologic settings,” said Dr. Dan Barouch, a virus expert at Beth Israel Deaconess Medical Center in Boston who has led some studies for J&J but was not involved in the trial. “This is very good news for the fight against the global COVID-19 pandemic.”

The South African researchers recorded two cases of the rare clotting disorder associated with the Johnson & Johnson vaccine in the trial; both participants made a complete recovery.

This article originally appeared in The New York Times.


c.2021 The New York Times Company